These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 28687713

  • 1. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC.
    Clin Sci (Lond); 2017 Aug 15; 131(16):2145-2159. PubMed ID: 28687713
    [Abstract] [Full Text] [Related]

  • 2. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, Nguyen T, Heydet D, Delghingaro-Augusto V, Nolan CJ, Shackel NA, McLennan SV, Teoh NC, Larter CZ.
    Liver Int; 2014 Aug 15; 34(7):1084-93. PubMed ID: 24107103
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.
    J Gastroenterol Hepatol; 2012 Feb 15; 27(2):341-50. PubMed ID: 21929649
    [Abstract] [Full Text] [Related]

  • 4. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ, Yeh MM, Haigh WG, Van Rooyen DM, Brooling J, Heydet D, Nolan CJ, Teoh NC, Farrell GC.
    Obesity (Silver Spring); 2013 Jun 15; 21(6):1189-99. PubMed ID: 23666886
    [Abstract] [Full Text] [Related]

  • 5. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S, Rousseau D, Bonnafous S, Lebeaupin C, Luci C, Canivet CM, Schneck AS, Bertola A, Saint-Paul MC, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-Maitre B, Gual P.
    J Hepatol; 2017 Aug 15; 67(2):328-338. PubMed ID: 28323124
    [Abstract] [Full Text] [Related]

  • 6. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC.
    J Gastroenterol Hepatol; 2009 Oct 15; 24(10):1658-68. PubMed ID: 19788606
    [Abstract] [Full Text] [Related]

  • 7. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, Castro RE, Rodrigues CM.
    Clin Sci (Lond); 2015 Oct 01; 129(8):721-39. PubMed ID: 26201023
    [Abstract] [Full Text] [Related]

  • 8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 9. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.
    Zhang X, Fan L, Wu J, Xu H, Leung WY, Fu K, Wu J, Liu K, Man K, Yang X, Han J, Ren J, Yu J.
    J Hepatol; 2019 Jul 16; 71(1):163-174. PubMed ID: 30914267
    [Abstract] [Full Text] [Related]

  • 10. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC, Haczeyni F, Chitturi S.
    Adv Exp Med Biol; 2018 Jul 16; 1061():19-44. PubMed ID: 29956204
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J.
    J Hepatol; 2020 Apr 16; 72(4):627-635. PubMed ID: 31760070
    [Abstract] [Full Text] [Related]

  • 12. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M, Vila-Bedmar R, Arcones AC, González-Rodríguez Á, Rada P, Gutiérrez-de-Juan V, Vargas-Castrillón J, Iruzubieta P, Sánchez-González C, Formentini L, Crespo J, García-Monzón C, Martínez-Chantar ML, Valverde ÁM, Mayor F, Murga C.
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec 16; 1864(12):3655-3667. PubMed ID: 30261289
    [Abstract] [Full Text] [Related]

  • 13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC.
    J Hepatol; 2017 May 16; 66(5):1037-1046. PubMed ID: 28167322
    [Abstract] [Full Text] [Related]

  • 14. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.
    Legry V, Van Rooyen DM, Lambert B, Sempoux C, Poekes L, Español-Suñer R, Molendi-Coste O, Horsmans Y, Farrell GC, Leclercq IA.
    Clin Sci (Lond); 2014 Oct 16; 127(7):507-18. PubMed ID: 24766485
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
    Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, Teoh NC, Farrell GC.
    J Hepatol; 2013 Jul 16; 59(1):144-52. PubMed ID: 23500152
    [Abstract] [Full Text] [Related]

  • 16. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.
    Ye D, Yang K, Zang S, Lin Z, Chau HT, Wang Y, Zhang J, Shi J, Xu A, Lin S, Wang Y.
    J Hepatol; 2016 Nov 16; 65(5):988-997. PubMed ID: 27266617
    [Abstract] [Full Text] [Related]

  • 17. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S, Muench GA, Shang L, Rosenthal SB, Rahman G, Wang R, Wang Y, Kwon HC, Diomino AM, Kisseleva T, Soorosh P, Hosseini M, Knight R, Schnabl B, Brenner DA, Dhar D.
    Cell Mol Gastroenterol Hepatol; 2021 Nov 16; 12(3):891-920. PubMed ID: 34062281
    [Abstract] [Full Text] [Related]

  • 18. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
    Hu J, Wang H, Li X, Liu Y, Mi Y, Kong H, Xi D, Yan W, Luo X, Ning Q, Wang X.
    Theranostics; 2020 Nov 16; 10(21):9702-9720. PubMed ID: 32863955
    [Abstract] [Full Text] [Related]

  • 19. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q, Zhou H, Bu Q, Wei S, Li L, Zhou J, Zhou S, Su W, Liu M, Liu Z, Wang M, Lu L.
    J Hepatol; 2022 Aug 16; 77(2):312-325. PubMed ID: 35292349
    [Abstract] [Full Text] [Related]

  • 20. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.
    Zhang X, Han J, Man K, Li X, Du J, Chu ES, Go MY, Sung JJ, Yu J.
    J Hepatol; 2016 Jan 16; 64(1):160-70. PubMed ID: 26394162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.